Earlier Blood Biomarker Disclosure Boosts Diagnostic Certainty in Memory Clinic

A randomized trial at a Spanish memory clinic tested earlier versus delayed disclosure of plasma p-tau217 and NfL results in 220 outpatients with subjective cognitive decline, MCI, or mild dementia. The trial reported that earlier disclosure increased very high-confidence etiologic diagnoses (50.0% vs 4.6% at 3 months), was associated with more frequent initiation of symptomatic AD treatment, fewer follow-up neuropsychological reassessments, and more discharges to primary care, without worsening emotional outcomes.

Most relevant for: Patients being evaluated in memory clinics for subjective cognitive decline, mild cognitive impairment, or mild dementia without an established etiologic diagnosis.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.